U.S. Pharmacist

Advertisement
Advertisement

Thrombolytic Therapy in Pregnant Women

Rolando Torres-Colón, PharmD
Assistant Professor, Department of Pharmaceutical Sciences and Administration
Nova Southeastern University,
Ponce, Puerto Rico

Eric Frontera-Zayas, PharmD
Community Pharmacy Resident
NSU Clinic Pharmacy,
Fort Lauderdale, Florida

Maria Maniscalco-Feichtl, PharmD
Assistant Professor, Department of Pharmacy Practice,
Nova Southeastern University,
Fort Lauderdale, Florida

9/19/2007

US Pharm. 2007;32(9):HS-12-HS-15.

Pregnancy has been identified as a condition prone to thrombosis and embolism, although there is limited published information regarding treatment options for thrombosis in pregnant women.1 Pregnancy could be considered as the initiation of a hypercoagulable state that lasts for a period of 11 months--10 months of pregnancy and one month postpartum.2 Due to the physiologic changes that occur in pregnancy, the coagulation cascade's response is altered in order to minimize blood loss during gestation and delivery. While hemorrhage and embolism are common causes of death in pregnancy, venous thromboembolism is a leading cause of maternal deaths. 3,4 Compared to nonpregnant women, the risk of venous thromboembolism during pregnancy and after delivery is increased about fivefold.5 Thromboembolic complications in the United States occur in about 1 in 1,000 pregnancies and in approximately 1 in 5,000 deliveries.4-6 

Thrombolytic agents available in the U.S. are alteplase (tissue plasminogen activator [t-PA], recombinant t-PA [rt-PA]), reteplase, streptokinase, urokinase, and tenecteplase. Currently, clinical guidelines regarding the use of thrombolytic agents in pregnant women who present with an active clot are nonexistent. Yet, numerous case reports have been published regarding the use of these agents in pregnant women. This article provides a brief overview of the use of thrombolytic agents in pregnant women. Indirect (e.g., low-molecular-weight heparin and heparin) and direct (e.g., argatroban, bivalirudin, and lepirudin) thrombin inhibitors will not be discussed.

Etiology of Thrombosis in Pregnancy
Increased levels of estrogen and certain coagulation factors are key components in the development of a hypercoaguable state during pregnancy.4 These elements can lead to venous distension, potentially resulting in venous stasis, and increased levels of coagulation factors with a subsequent increased rate of activity.7 These mechanisms are thought to be the cause of the higher rates of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and thrombosis of cardiac valvular prosthesis in pregnancy.8-10 Untreated DVT may result in PE in up to 24% of pregnant patients, with an associated mortality rate of approximately 15%.4 In addition, pregnancy has been shown to cause a significant decrease in the production of natural anticoagulant protein S and an increase in the development of acquired activated protein C resistance.7,11

There are three components, known as Virchow's triad (VT), that can lead to the formation of a thrombus: blood vessels, circulating elements in the blood, and the speed of blood flow.12 An irregularity of any component of the VT may cause thrombosis and embolism, which can reduce blood flow to critical organs.1

Mechanisms and Adverse Effects of Thrombolytic Therapy
Contraindications to the use of thrombolytic agents in pregnancy is relative to the patient, and consideration of the benefits versus the risks of treatment is an important step prior to administration. All thrombolytic agents work by activating plasminogen, which ultimately results in the degradation of fibrin clots. The human fibrinolytic system stimulates the release of tissue plasminogen activator from endothelial cells in response to various signals or injuries. Tissue plasminogen activator binds to plasminogen within the clot and converts to plasmin. The enzyme plasmin (a nonspecific protease) digests fibrin (protein that forms a "mesh") clots and several coagulation factors. The human fibrinolytic system is regulated in such a way that unwanted fibrin clots are removed from circulation while simultaneously leaving desired fibrin in wounds intact to maintain hemostasis.1,12,13 Therefore, clot dissolution is known as a product of fibrin degradation. Plasminogen and plasmin bind to fibrin at binding sites located near the amino termini that are located in the lysine residues. The lysine residues are also a site for alpha-2-antiplasmin, which covalently binds to fibrin, thereby protecting it from premature lysis. When plasminogen activators are administered for thrombolytic therapy, massive fibrinolysis is initiated and the inhibitory controls are overwhelmed.13 Exogenously administered thrombolytic agents not only dissolve the pathological thrombi but also dissolve the surrounding fibrin deposits at the site of injury.

Thus, the major side effect of thrombolytic administration is hemorrhage.12 The use of thrombolytics may cause several complications. Major adverse events include life-threatening hemorrhage (i.e., uterine and postpartum), intracranial hemorrhage, and incomplete clot dissolution that may lead to embolization. 12,13

The ideal thrombolytic agent would induce local pathological clot dissolution without producing systemic fibrinolysis or disrupting physiologic thrombi necessary for normal hemostatic balance.14 Since there is no ideal thrombolytic agent, a variety of adjunctive therapies (e.g., aspirin, clopidogrel, and heparin) are required to achieve all of the hemostatic goals.14 Because aspirin and clopidogrel are not indicated for use in pregnant patients, heparin or low-molecular-weight heparin are the only options for thrombus prophylaxis.

It is difficult to choose a thrombolytic therapy for a pregnant patient when the package insert indicates a pregnancy category C and the major adverse event is hemorrhage. There is always the concern of entry of the drug into the placenta. However, several factors influence the transfer of drugs to the placenta, such as molecular weight, lipid solubility, drug pH, and binding to plasma proteins. Molecular weight is the most important factor to consider when addressing the use of thrombolytic agents in pregnancy. Drugs with molecular weights greater than 1,000 Da often poorly cross the placenta.15 Thus, thrombolytic agents are unlikely to cross the placenta due to their large molecular weight 16 (see Table 1).



Diagnosis of Clotting Disorders During Pregnancy
Early diagnosis of clotting disorders is important to prevent complications. Most diagnostic procedures have excluded pregnant women; therefore, it is difficult to formulate an evidence-based recommendation.

DVT begins in the calf or in the ileofemoral segment, with a tendency to occur in the left leg due to compression of the iliac vein by the gravid uterus (uterus containing a developing fetus). Noninvasive studies, such as impedance plethysmography (the measurement of blood volume changes) and ultrasonography, are recommended as initial diagnostic tools for clots in pregnancy. However, if isolated iliac vein thrombosis is suspected and if the veins cannot be identified by ultrasonography or venography, a more complex and invasive procedure could be considered.18

PE can be difficult to diagnose, especially in pregnant women. Symptoms of PE should be interpreted with caution during pregnancy because dyspnea, tachypnea, and chest discomfort are already common. Electrocardiogram, chest radiographs, and arterial blood gas may support a PE diagnosis. In addition, a lung scan, also known as a ventilation perfusion scan, is the primary screening tool for the diagnosis in pregnant patients but exposes the fetus to radiation (although the amount has not been associated with significant risk of fetal injury). 18

Stroke, the loss of brain function due to interruption of blood supply, is a risk factor in pregnant patients. A pregnant woman experiences natural changes from an elevation in blood pressure and stress on the heart, which increases the risk of stroke. Common clinical presentations of stroke symptoms include headache, focal neurologic deficit, seizures, and visual changes. Clinicians should perform a neurologic examination, a funduscopic examination to assess intracranial pressure, as well as cardiovascular and skin examinations. In addition, tests such as CT and MRI may be performed.10 However, the use of MRI during the first trimester should be avoided.18

Risk Factors for Venous Thromboembolism in Pregnant Patients
The management of pregnant women with known thrombophilic defects and no prior history of thromboembolism remain controversial. Information is limited regarding the natural history of the various thrombophilia, and there is a lack of appropriate trials for prophylaxis. Pregnant women with previous thrombosis events may be at risk of a recurrent event. Women with a history of venous thromboembolism and inherited thrombophilia (i.e., protein C and S deficiency, factor V Leiden, prothrombin G20210A, and antithrombin) may be classified as being at a high, moderate, or slightly increased risk of thromboembolic events during pregnancy (Table 2).19



Case Reports
Since there are no existing randomized, controlled trials to evaluate the use of thrombolytics agents during pregnancy, cases reported in the literature will be reviewed.

In a case report by Yap et al., a 28-year-old woman in week 30 of her pregnancy who presented with PE received rt-PA 10 mg IV bolus, followed by 90 mg over two hours. The patient's hemodynamic status improved. A healthy baby boy was born by vaginal delivery at 36 weeks' gestation.20

In a report by Patel et al., a 36-year-old woman presented at 20 weeks' gestation with a five-day history of worsening breathlessness, chest pain, and palpitations. The diagnosis of massive PE was made, and rt-PA was administered at 10 mg bolus, followed by a 90 mg infusion over two hours. There was an improvement of blood pressure from 67/40 to 120/80 mmHg. After discontinuing thrombolytic therapy, she received unfractionated heparin for 48 hours, followed by low-molecular-weight heparin. The fetal outcome was not reported.21

In a case reported by Flobdorf et al., a 27-year-old pregnant woman at 31 weeks' gestation was admitted to the hospital with respiratory distress and tachypnea. She was diagnosed with massive PE. Initial treatment was urokinase, but this medication was switched to rt-PA 10 mg over four hours, followed by 2 mg over 1.5 hours. Forty-eight hours after thrombolysis, the patient delivered a healthy infant. Maternal outcomes were reported as stable.22

In another report by Ahearn et al., a 12-week pregnant, 36-year-old African-American woman presented with acute dyspnea and substernal chest pain in the emergency department. The patient was lethargic with a blood pressure of 82/50 mmHg and a pulse of 135 beats per minute. She was diagnosed with massive PE. The patient received 100 mg of rt-PA over two hours. Maternal outcomes were reported to be stable, and the patient delivered a full-term infant without complications.23

A case reported by Elford et al. describes a 28-year-old, newly gravid woman with a seven-year history of primary infertility and four unsuccessful cycles of ovulation induction. The patient presented with dysarthria, left facial paralysis, and drowsiness; she was diagnosed with a stroke that was confirmed by CT. The patient was administered 15.5 mg of intra-arterial rt-PA. Over a three-week period, the patient regained hematologic and neurologic stability. She delivered a healthy male infant at term by vaginal delivery.24

Murugappan et al. reported on eight pregnant women diagnosed with acute ischemic stroke who were treated with either rt-PA or urokinase. The average maternal age was 32 years and the mean gestational age was 11 weeks (range, 4-37 weeks). Etiologies of stroke were varied (e.g., discontinuation of anticoagulants in patients with mechanical heart valves, hypercoaguable states). Four women were treated with rt-PA, and the other four were treated with urokinase. One of the mothers died secondary to complications of angioplasty. This death was determined by the authors to not be caused solely by thrombolytic therapy. Of the mothers who survived, three elected to have therapeutic abortions, two miscarried within two to three days of urokinase administration, and two mothers delivered at term without any complications (one received rt-PA and the other received urokinase).25

A 27-year-old pregnant woman in her first trimester was hospitalized due to pregnancy complications for three weeks. Her clinical condition deteriorated and she developed shock, followed by cardiac arrest. The diagnosis was consistent with acute PE, and the patient received streptokinase. This treatment was complicated by massive bleeding due to the rupture of the uterus. She underwent hysterectomy and recovered thereafter. No further information was provided on the patient's condition.26

Role of the Pharmacist
As the pathophysiology of thrombus formation becomes increasingly understood, new therapeutic options have emerged and the role of existing pharmacotherapeutic agents has expanded. Each thrombolytic agent has its own specific dosing regimen, typically based on the clotting disorder being treated. Pharmacists can have an integral role in drug selection based on patient-specific parameters. In addition, therapeutic monitoring is essential for adequate and sustained patient care in order to avoid adverse effects. This includes monitoring for any sign of bleeding, allergic reactions, and in some instances, improvement for clinical outcomes. Through close patient interaction and attention to specific symptoms, pharmacists can help patients avoid potential complications and achieve appropriate goals.

Conclusion
The majority of cases presented in this article resulted in encouraging outcomes. In one case, the use of hormones for fertility was thought to be the cause of thrombus formation. This substantiates the documented risk of hormone use in the development of thromboembolic events and illustrates the need for pharmacists to be aware of the increased risk of thrombosis in women who use fertility agents.7,13 In terms of maternal mortality, all cases presented positive outcomes. Regarding fetal outcomes, one case did not report the outcome, while most of the remaining cases reported positive fetal outcomes. It is interesting to note that rt-PA was the drug of choice to treat a pregnant patient in the cases reported. The reason for this decision could be that rt-PA has the least potential to cause antigenicity and has the largest molecular weight in comparison to all the other thrombolytic agents.14

Generally, the use of thrombolytic therapy during pregnancy cannot be recommended until further safety and efficacy data are available. However, based on the cases assessed in this article, it appears that the use of a thrombolytic agent, particularly rt-PA, may be an effective therapeutic option for pregnant women who present with life-threatening blood clots.

References

1. Handin R. Hematologic alterations. In: Harrison's Principles of Internal Medicine. [book online]. The McGraw-Hill. 2005. Available at: www.accessmedicine.com.novacat.nova.edu. Accessed May 3, 2007.

2. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996;335:108-114.

3. MacKay AP, Berg CJ, Duran C, et al. An assessment of pregnancy-related mortality in the United States. Paediatr Perinat Epidemiol.2005;19:206-214.

4. Doyle N, Monga M. Thromboembolic disease in pregnancy. Obstet Gynecol Clin North Am. 2004;31:319-344.

5. Berg CJ, Atrash HK, Koonin LM, et al. Pregnancy related mortality in the United States, 1987-1990. Obstet Gynecol. 1996;88:161-167.

6. Lestsky W, Swiet M. Maternal hemostasos: coagulation problems of pregnancy. In: Loscalzo J, Schafer A, editors. Thrombosis and Hemorrhage. Boston, MA: Blackwell Scientific, 1994:965-998.

7. Bendell J, Benz EJ. Hematologic changes in pregnancy. In: Hoffman R, Benz Jr, Shanttil SJ, et al., editors. Hematology: Basic Principal and Practice. 4th ed.. Philadelphia, PA: Churchill Levingstone; 2005.

8. Leonhardt G, Gasul C, Nietsch HH, et al. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006;21:271-276.

9. Chan WS, SDC, Ginsberg JS. Antithrombotic therapy during pregnancy. Semin Perinatol. 2001;25:165-169.

10. Turan TN, Stern B. Stroke in pregnancy. Neurol Clin. 2004;22:821-840.

11. Gordon MC. Maternal physiology in pregnancy. In: Gabbe SG, Niebyl JR, Simpson JL, editors. Obstetrics: Normal and Problem Pregnancies. 4th ed. Philadelphia, PA: Churchill Levingstone; 2002:63-91.

12. Majerus PW, Broze Jr GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Dipiro J, Talbert RL, Yee JC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 3rd ed. Stamford, CT: McGraw-Hill; 1997.

13. Haines ST, Racine E, Zeolla M. Venous thromboembolism. In: Dipiro J, Talbert RL, Yee JC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. Stamford, CT: McGraw-Hill, 2002.

14. Baker W. Thrombolytic therapy Clinical applications. Hematol Oncol Clin N Am. 2003;17:283-311.

15. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487-514.

16. Briggs GG, Freeman RK., Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. [electronic resource]. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.

17. Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;1:34.

18. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996;335:108-114.

19. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol . 2001;114:512-528.

20. Yap LB, Alp NG, Forfar JC. Thrombolysis for acute massive pulmonary embolism during pregnancy. Int J Cardiol. 2002;82:193-194. Letter.

21. Patel RK, Fasan O, Arya R. Thrombylsis in pregnancy. Thromb Haemost. 2003;90:1216-1217. Letter.

22. Flobdorf TH, Breulmann M, Hopf H. Successful treatment of massive pulmonary embolism with recombinant tissue plasminogen activator (rt-PA) in a pregnant woman with intact gravity and preterm labour. Intensive Care Med. 1990;16:454-456.

23. Ahearn GS, Hadjiliadis D, Govert JA , et al. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissues plasminogen activator. Arch Intern Med. 2002;162:1221-1227.

24. Elford K, Leader A, Wee R, et al. Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA. Neurology. 2002;59:1270-1272.

25. Murugappan A, Coplin WM, Al-Sadat AN, et al. Thrombolytic therapy for acute ischemic stroke during pregnancy. Neurology. 2006;66:678-770.

26. Kukla P, Borowicz J, Szczuka K, et al. Massive pulmonary embolism during pregnancy treated with streptokinase and complicated by massive hemorrhage -a case report. Kardiol Pol. 2004;60:505-509. [Abstract]

To comment on this article, contact uspharmacist.com.

Advertisement

U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Copyright © 2000 - 2014 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.